193 related articles for article (PubMed ID: 21651481)
1. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.
Marrelli M; Conforti F; Statti GA; Cachet X; Michel S; Tillequin F; Menichini F
Curr Med Chem; 2011; 18(20):3035-81. PubMed ID: 21651481
[TBL] [Abstract][Full Text] [Related]
2. Combretastatin A-4 analogues as antimitotic antitumor agents.
Nam NH
Curr Med Chem; 2003 Sep; 10(17):1697-722. PubMed ID: 12871118
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy.
Faustino C; Francisco AP; Isca VMS; Duarte N
Curr Pharm Des; 2018; 24(36):4270-4311. PubMed ID: 30636588
[TBL] [Abstract][Full Text] [Related]
4. The biology of the combretastatins as tumour vascular targeting agents.
Tozer GM; Kanthou C; Parkins CS; Hill SA
Int J Exp Pathol; 2002 Feb; 83(1):21-38. PubMed ID: 12059907
[TBL] [Abstract][Full Text] [Related]
5. Tubulin-interactive stilbene derivatives as anticancer agents.
Mikstacka R; Stefański T; Różański J
Cell Mol Biol Lett; 2013 Sep; 18(3):368-97. PubMed ID: 23818224
[TBL] [Abstract][Full Text] [Related]
6. Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.
Karatoprak GŞ; Küpeli Akkol E; Genç Y; Bardakci H; Yücel Ç; Sobarzo-Sánchez E
Molecules; 2020 May; 25(11):. PubMed ID: 32486408
[TBL] [Abstract][Full Text] [Related]
7. Development of combretastatins as potent tubulin polymerization inhibitors.
Bukhari SNA; Kumar GB; Revankar HM; Qin HL
Bioorg Chem; 2017 Jun; 72():130-147. PubMed ID: 28460355
[TBL] [Abstract][Full Text] [Related]
8. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
[TBL] [Abstract][Full Text] [Related]
9. Combretastatin A4 phosphate: background and current clinical status.
Young SL; Chaplin DJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
[TBL] [Abstract][Full Text] [Related]
10. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a).
Pettit GR; Singh SB; Boyd MR; Hamel E; Pettit RK; Schmidt JM; Hogan F
J Med Chem; 1995 May; 38(10):1666-72. PubMed ID: 7752190
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumour vasculature: the development of combretastatin A4.
Griggs J; Metcalfe JC; Hesketh R
Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
[TBL] [Abstract][Full Text] [Related]
12. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
Lin CM; Singh SB; Chu PS; Dempcy RO; Schmidt JM; Pettit GR; Hamel E
Mol Pharmacol; 1988 Aug; 34(2):200-8. PubMed ID: 3412321
[TBL] [Abstract][Full Text] [Related]
13. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
[TBL] [Abstract][Full Text] [Related]
14. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
Liu L; Mason RP; Gimi B
Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
[TBL] [Abstract][Full Text] [Related]
15. Developments of combretastatin A-4 derivatives as anticancer agents.
Shan Y; Zhang J; Liu Z; Wang M; Dong Y
Curr Med Chem; 2011; 18(4):523-38. PubMed ID: 21143124
[TBL] [Abstract][Full Text] [Related]
16. Disrupting tumour blood vessels.
Tozer GM; Kanthou C; Baguley BC
Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
[TBL] [Abstract][Full Text] [Related]
17. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
18. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
19. New vascular disrupting agents in upper gastrointestinal malignancies.
Quatrale AE; Porcelli L; Gnoni A; Numico G; Paradiso A; Azzariti A
Curr Med Chem; 2014; 21(8):1039-49. PubMed ID: 23992324
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
